Thus the comparative effectiveness of SGLT-2 inhibitors versus alternative second line oral antidiabetic treatments on outcomes important to people with type 2 diabetes mellitus, particularly reduction in HbA1c level, remains unclear. Here, SLC5A2 is linked to type 2 diabetes mellitus.